奥曲肽联合加大补液量治疗肝硬化难治性腹水的效果观察

戈宏焱; 李培霞; 张洋洋; 王丽丽; 魏耀玲

doi:10.3969/j.issn.1001-5256.2018.01.020

奥曲肽联合加大补液量治疗肝硬化难治性腹水的效果观察

DOI: 10.3969/j.issn.1001-5256.2018.01.020

1. 内蒙古民族大学附属医院消化内科
2. 内蒙古民族大学临床医学院
3. 泰山医学院研究生院

详细信息

中图分类号: R575.2
计量
- 文章访问数: 2586
- HTML全文浏览量: 55
- PDF下载量: 406
- 被引次数: 15
出版历程
- 出版日期: 2018-01-20

Clinical effect of octreotide combined with an increased amount of fluid infusion in treatment of intractable cirrhotic ascites

Department of Gastroenterology, Affiliated Hospital of Inner Mongolia University for The Nationalities, Tongliao, Inner Mongolia 028000, China

摘要

摘要:
目的通过观察奥曲肽联合加大补液量对肝硬化难治性腹水的疗效,为临床提供新的诊疗思路。方法收集2016年2月-2017年5月就诊于内蒙古民族大学附属医院的肝硬化难治性腹水患者65例,随机分为对照组（n=31）和观察组（n=34）。对照组给予常规治疗;观察组在常规治疗的基础上给予奥曲肽0.6 mg,1次/12 h,持续泵入3 d后,改为0.2 mg,1次/8 h,皮下肌注,连续应用710 d,并加大补液量,其余治疗根据患者自身症状及机体耐受情况给予对症处理。观察治疗期间患者的生命体征、腹围、体质量及腹水消退时间,统计患者住院天数及并发症的发生率。计量资料组间比较采用t检验;计数资料组间比较采用χ2检验。结果观察组患者腹水消退时间及住院天数均短于对照组,差异均有统计学意义[（6.13±1.25）d vs（11.61±1.34）d,t=-4.06,P<0.001;（10.01±1.46）d vs（16.10±1.57）d,t=-7.65,P<0.001];腹围平均每天减少量、体质量平均每天减少量均高于对照组,差异均有统计学意义[（4.01±...
- 肝硬化 /
- 腹水 /
- 奥曲肽 /
- 补液疗法 /
- 治疗结果
Abstract:
Objective To investigate the clinical effect of octreotide combined with an increased amount of fluid infusion in the treatment of intractable cirrhotic ascites, and to provide new thoughts for clinical diagnosis and treatment. Methods A total of 65 patients with intractable cirrhotic ascites who visited Affiliated Hospital of Inner Mongolia University for The Nationalities from February 2016 to May 2017 were enrolled and randomly divided into control group with 31 patients and observation group with 34 patients. The patients in the control group were given conventional treatment, and those in the observation group were given continuous pumping of octreotide 0. 6 mg once every 12 hours for 3 days, followed by intramuscular injection of octreotide 0. 2 mg once every 8 hours for 7-10 consecutive days, and an increased amount of fluid infusion, in addition to the conventional treatment. Symptomatic treatment was given based on patients' symptoms and tolerance. Vital signs, abdominal circumference, body weight, and time to ascites regression were observed during treatment, and the length of hospital stay and incidence rate of complications were analyzed. The t-test was used for comparison of continuous data between groups, and the chi-square test was used for comparison of categorical data between groups. Results Compared with the control group, the observation group had significantly shorter time to ascites regression ( 6. 13 ± 1. 25 d vs 11. 61 ± 1. 34 d, t =-4. 06, P < 0. 001) and length of hospital stay ( 10. 01 ± 1. 46 d vs 16. 10 ± 1. 57 d, t =-7. 65, P < 0. 001) , as well as significantly greater average daily reductions in abdominal circumference ( 4. 01 ± 0. 75 cm vs 2. 42 ± 0. 35 cm, t = 4. 69, P < 0. 001) and body weight ( 1. 67 ± 0. 42 kg vs 0. 97 ± 0. 54 kg, t = 4. 58, P < 0. 001) . The observation group had significantly lower incidence rates of upper gastrointestinal bleeding and electrolyte disturbance than the control group ( upper gastrointestinal bleeding: 5. 88% vs 32. 26% , χ2= 7. 49, P < 0. 05; electrolyte disturbance: 8. 82% vs 38. 71% , χ2= 8. 56, P < 0. 05) . Conclusion In addition to the conventional treatment of intractable ascites, octreotide combined with an increased amount of fluid infusion can promote spontaneous dieresis, significantly reduce the amount of ascites, shorten the time to ascites regression, reduce complications, and improve patients' conditions.
- liver cirrhosis /
- ascites /
- octreotide /
- fluid therapy /
- treatment outcome

HTML全文

参考文献(15)

[1]ARROYO V, GINES P, GERBES AL, et al.Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis[J].Hepatology, 1996, 23 (1) :164-176.

[2]CHEN Y, ZHOU L.Research advances in treatment of cirrhotic ascites[J].J Clin Hepatol, 2016, 32 (6) :1069-1074. (in Chinese) 陈煜, 周莉.肝硬化腹水治疗的新进展[J].临床肝胆病杂志, 2016, 32 (6) :1069-1074.

[3]SANGIOVANNI A, PRATI GM, FASANI P, et al.The natural history of compensated cirrhosis due to hepatitis C virus:a 17-year cohort study of 214 patients[J].Hepatology, 2006, 43 (6) :1303-1310.

[4]GE JB, XU YJ.Internal Medicine[M].8th ed.Beijing:People's Medical Publishing House, 2013:419-428. (in Chinese) 葛均波, 徐永健.内科学[M].8版.北京:人民卫生出版社, 2013:419-428.

[5]LIN PC, LIN YK, LI YB, et al.Advances in the treatment of cirrhotic ascites[J].Mod J Integr Tradit Chin West Med, 2014, 23 (29) :3299-3301. (in Chinese) 林培淳, 林勇凯, 李艺滨, 等.肝硬化腹水治疗进展[J].现代中西医结合杂志, 2014, 23 (29) :3299-3301.

[6]OCHS A, ROSSLE M, HAAG K, et al.The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites[J].N Engl J Med, 1995, 332 (18) :1192-1197.

[7]SINGHAL S, BAIKATI KK, JABBOUR II, et al.Management of refractory ascites[J].Am J Ther, 2012, 19 (2) :121-132.

[8]European Association for the Study of the Liver.EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis[J].J Hepatol, 2010, 53 (3) :397-417.

[9]LIU HH, LUO SQ, FU JL, et al.Advances in the treatment of intractable cirrhotic ascites[J].J Pract Hepatol, 2011, 14 (4) :317-320. (in Chinese) 刘红虹, 罗生强, 福军亮, 等.肝硬化顽固性腹水的治疗新进展[J].实用肝脏病杂志, 2011, 14 (4) :317-320.

[10]SCHRIER RW.Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy[J].N Engl J Med, 1988, 319 (17) :1127-1134.

[11]FORTUNE B, CARDENAS A.Ascites, refractory ascites and hyponatremia in cirrhosis[J].Gastroenterol Rep (Oxf) , 2017, 5 (2) :104-112.

[12]ZHANG JL, LIU JL, LI YG, et al.The treatment discussion of refractory ascites in the cirrhosis of the liver[J].J World Latest Med Inf, 2016, 16 (100) :52-53, 56. (in Chinese) 张俊立, 刘静丽, 李艳歌, 等.肝硬化难治性腹水的治疗探讨[J].世界最新医学信息文摘, 2016, 16 (100) :52-53, 56.

[13]GUO LX.Clinical treatment in patients with liver cirrhosis refractory ascites[J].Chin Community Doct, 2016, 32 (35) :56, 58. (in Chinese) 郭丽仙.肝硬化难治性腹水的临床治疗观察[J].中国社区医师, 2016, 32 (35) :56, 58.

[14]ZHANG GQ.An analysis of clinical therapies for cirrhotic ascites[J].Chin J Mod Drug Appl, 2017, 11 (3) :133-135. (in Chinese) 张桂芹.肝硬化腹水临床的治疗方法分析[J].中国现代药物应用, 2017, 11 (3) :133-135.

[15]ZHU Q, JIANG XH, YI F, et al.The effects of octreotide on portal hemodynamics in patients with liver cirrhosis[J].Chin J Intern Med, 2004, 43 (1) :16-18. (in Chinese) 诸琦, 江晓华, 乙芳, 等.奥曲肽对肝硬化门脉血流动力学的影响[J].中华内科杂志, 2004, 43 (1) :16-18.

施引文献

期刊类型引用(12)

1.	芦建慧，李勇利，郭瑞芳，薛荣泉. 胆囊切除术后原发性胆总管结石复发患者的临床特征分析. 临床肝胆病杂志. 2025(01): 118-126 . 本站查看
2.	陈大勇，郭宏志，李权. 腹腔镜胆囊切除术联合同期内镜逆行胰胆管造影术治疗高龄胆囊结石合并继发性胆总管结石患者的效果. 河南医学研究. 2024(06): 1060-1063 . 百度学术
3.	仝甲钊，曹振振，孙正路，周从顺，魏书堂. 胆总管结石合并十二指肠乳头旁憩室老年患者ERCP取石成功的影响因素. 河南医学研究. 2024(08): 1358-1362 . 百度学术
4.	李梦珂，李渊，王建伟. 胆囊结石合并胆总管多发结石治疗效果及其logistic回归分析. 黑龙江医学. 2024(17): 2054-2057 . 百度学术
5.	范嗣琪，魏然，魏杰，李富贵. 乳头夹闭成型+胆总管取石术治疗胆总管结石伴急性胆管炎的应用体会. 腹腔镜外科杂志. 2024(10): 741-746 . 百度学术
6.	李泳，周鸿鲲. 不同手术方法治疗胆囊切除后胆总管结石患者的临床疗效分析. 浙江创伤外科. 2023(06): 1118-1120 . 百度学术
7.	雷文俤，常贵建，卓信斌，林德新. 胆道冲洗装置在腹腔镜胆总管切开取石术中的应用体会. 腹腔镜外科杂志. 2023(08): 604-608 . 百度学术
8.	刘小红，刘洋，武起美. 肾结石行微创手术患者术后复发的影响因素及其防护对策分析. 内蒙古医学杂志. 2023(07): 875-877 . 百度学术
9.	吴灵燕，王晓荣，陈柳勇，徐陈柯，黄作斌. 超声联合CT检查在胆总管结石诊断中的应用价值及其漏诊的相关因素分析. 浙江创伤外科. 2023(07): 1372-1374 . 百度学术
10.	林秀苹，林洁君，郑艳莉. 彩色多普勒超声术前诊断胆囊结石效能及术后评估结石复发的危险因素分析. 浙江创伤外科. 2023(10): 1954-1957 . 百度学术
11.	云逸飞，王林恒，江贵，卢心毓，黄朔，何寅家，张丽杰. 单人经口胆道镜系统直视下与传统X线下非困难性胆总管结石取石的对比研究. 中华消化内镜杂志. 2023(09): 707-712 . 百度学术
12.	王亮，陈信浩. 腹腔镜胆囊切除术联合胆总管探查术治疗胆总管结石对患者肝功能及炎性应激反应的影响. 药物生物技术. 2023(06): 614-617 . 百度学术